Compensation InsightHow Sonic Healthcare Pays
A comprehensive analysis of Sonic Healthcare's career levels, compensation by role, equity plans, executive pay, pathologist earnings, and global operations across Australia, USA, UK, Germany, and Switzerland.
At a Glance
Career Level Hierarchy
Sonic Healthcare uses a federated model without a single public band system. This hierarchy is inferred from job postings, LinkedIn titles, and Glassdoor data. Clinical staff (pathology collectors, scientists) are governed by the Health Professionals & Support Services Award 2020.
Pathologist Track (Separate from Corporate)
HPSS Award Coverage (Australia)
Under the Health Professionals and Support Services Award 2020, pathology collectors and lab support staff are classified into Levels 1–9 (weekly pay A$910.90 to A$1,331.60). In April 2025, the Fair Work Commission proposed reclassifying pathology collectors with Certificate IV to Level 7, resulting in 1.8–10.9% wage increases. A 3.5% general wage increase also took effect July 2025.
Federated Model
Sonic Healthcare operates through a federated model where each division (Sullivan Nicolaides, Douglass Hanly Moir, Melbourne Pathology, Clinipath, TDL, Bioscientia, etc.) maintains operational autonomy with local branding and management. Medical leadership is a core principle — pathologists lead medical operations at every level.
Compensation by Level
Total compensation breakdown for Sydney, Australia. All values in AUD.
| Level | Title | Base (Range) | Variable % | Total Comp (Range) | Equity |
|---|---|---|---|---|---|
| S1 | Support/Admin 0–1 yrs | A$45K – A$55K | 0% | A$50K – A$62K | None |
| S2 | Associate/Collector 0–2 yrs | A$55K – A$68K | 0% | A$62K – A$77K | None |
| S3 | Professional 1–4 yrs | A$70K – A$95K | 5% | A$79K – A$108K | None |
| S4 | Senior Professional 3–7 yrs | A$95K – A$135K | 10% | A$108K – A$155K | Employee Option Plan |
| S5 | Manager 5–10 yrs | A$130K – A$180K | 15% | A$152K – A$215K | Employee Option Plan |
| S6 | Sr Manager/Director 8–15 yrs | A$180K – A$260K | 20% | A$220K – A$330K | Performance Rights |
| S7 | Vice President 12–20 yrs | A$260K – A$400K | 30% | A$345K – A$540K | Performance Rights |
| S8 | Executive (CEO/CFO/COO/CMO) 18+ yrs | A$1.0M – A$1.8M | 100% | A$2.0M – A$5.2M | Performance Rights + Options |
Source: Glassdoor, PayScale, Sonic Healthcare Annual Report FY2025, Fair Work Commission HPSS Award. Australian values include superannuation (12% from Jul 2025).
Total Compensation Range by Level
Variable Pay & STI Payout History
Executive STI targets 100% of Fixed Remuneration (max 150%). 20% of STI is tied to qualitative strategic objectives including ESG/sustainability goals.
STI Payout History (% of Target)
Variable Pay % by Level
CEO STI History
| Year | CEO | STI Outcome | Context |
|---|---|---|---|
| FY2020 | Colin Goldschmidt | 0% | COVID-19 pandemic; volumes collapsed |
| FY2021 | Colin Goldschmidt | 150% | Massive COVID testing revenue |
| FY2022 | Colin Goldschmidt | 120% | Continued COVID testing |
| FY2023 | Colin Goldschmidt | 85% | COVID revenue declining |
| FY2024 | Colin Goldschmidt | 95% | Post-COVID normalization |
| FY2025 | Jim Newcombe | 105% | Strong organic growth |
Equity & Incentive Structure
Sonic Healthcare uses a mix of options, performance rights, and share purchase plans. Executive STI targets 100% of Fixed Remuneration with 150% maximum.
Active Plans
CEO Comp Structure (at Target)
Equity Eligibility by Level
| Level | Eligibility | Instrument | Typical Annual Grant |
|---|---|---|---|
| S1–S2 | None | N/A | — |
| S3 | Rare | Employee Option Plan | — |
| S4 | Selective | Employee Option Plan | A$5K–A$15K |
| S5 | Common | Options + rights | A$15K–A$50K |
| S6 | Standard | Performance Rights | A$50K–A$150K |
| S7 | Standard | Performance Rights | A$150K–A$500K |
| S8 | Mandatory | Rights + Options | 100–150% of FR |
| Pathologist | Selective | Performance Rights | Varies by practice |
Recent Grant Activity
- May 2024: 6,970,745 unquoted securities issued under employee incentive scheme
- September 2025: 49,661 performance rights granted to employees
- Share Purchase Plan: Up to A$15,000 per eligible shareholder
- Employee Share Trust: Subscribes and allocates shares on behalf of plan participants
STI Formula
STI = Fixed Remuneration × Target % × Performance Outcome
20% of STI is based on qualitative strategic objectives, with half of that tied to ESG/sustainability goals. Maximum STI is capped at 150% of Fixed Remuneration. Board retains full discretion.
ASX Insider Trades & Director Dealings
Disclosed to ASX under Corporations Act. Director purchases signal confidence; CEO/CFO disposals were noted totaling ~A$14.3M.
| Date | Person | Role | Type | Shares | Price (A$) | Value |
|---|---|---|---|---|---|---|
| Oct 2, 2025 | Mark Compton | Chairman | Acquisition | 1,500 | A$21.57 | A$32K |
| Oct 1, 2025 | Christine Bennett | Non-Exec Director | Acquisition | 1,100 | A$21.51 | A$24K |
| Mar 25, 2025 | Nicola Wakefield Evans | Non-Exec Director | Acquisition | 2,000 | A$25.60 | A$51K |
| Sep 2025 | Employee Incentive Plan | Performance Rights | Acquisition | 49,661 | Equity grant | Deferred equity |
| May 2024 | Employee Incentive Scheme | Equity Grant | Acquisition | 6,970,745 | Equity grant | Deferred equity |
| FY2024 | Colin Goldschmidt | CEO & MD | Disposal | 280,000 | A$24.50 | A$6.9M |
| FY2024 | Chris Wilks | CFO & Finance Dir | Disposal | 300,000 | A$24.80 | A$7.4M |
Director Buying Signal
In October 2025, Chairman Mark Compton and Director Christine Bennett made on-market purchases totaling A$55,000+ when the share price was around A$21.50 — near 52-week lows (range: A$20.50–A$29.24). New director Nicola Wakefield Evans also purchased 2,000 shares in March 2025 at A$25.60. These purchases signal board confidence despite a 17% annual stock decline.
CEO/CFO Share Sales — A$14.3M
Outgoing CEO Dr Colin Goldschmidt and CFO Chris Wilks sold shares worth approximately A$14.3M combined during FY2024. While the sales raised questions about leadership alignment, they occurred in the context of the CEO's planned retirement (announced September 2025, effective November 20, 2025). Goldschmidt's remaining shareholding was valued at A$14.7M (0.2% of company) at time of disclosure.
Source: ASX announcements (Appendix 3Y), Sonic Healthcare Annual Report FY2025, TipRanks.
Executive Compensation — FY2024/25
| Year | FR | Total | Note |
|---|---|---|---|
| FY2021 | A$1.75M | A$7.2M | COVID testing peak; extraordinary STI |
| FY2022 | A$1.75M | A$5.8M | Continued elevated volumes |
| FY2023 | A$1.75M | A$4.5M | COVID revenue declining |
| FY2024 | A$1.75M | A$5.16M | Post-COVID normalization; final full year |
Senior Leadership Compensation
Sonic Healthcare's executive compensation includes Fixed Remuneration, STI (target 100% of FR, max 150%), and LTI (performance rights). 20% of STI is tied to qualitative strategic objectives including ESG.
Medical Leadership Principle
- CEO is a qualified pathologist — Dr Jim Newcombe (from Nov 2025)
- Board includes 1 pathologist and 3 other medical practitioners
- Divisional CEOs are often pathologists (e.g., DHM, SNP)
- Nearly 400 pathologists across Australian operations alone
- Federated model empowers local medical leadership
Benefits & Perks
Health & Financial
Leave
Career & Development
- Continuing Professional Development (CPD) — funded for pathologists and scientists
- Fellowship Support — assistance with RCPA, IBMS, and equivalent qualifications
- Laboratory Training Programs — structured rotations for graduates
- Leadership Development — programs for emerging leaders across divisions
- Conference & Journal Access — funded attendance at medical conferences
- Flexible Working — available across many roles; lab staff have shift flexibility
- Employee Share Purchase Plan (SPP) — up to A$15,000 per eligible shareholder
Performance & Pay Progression
Sonic Healthcare uses a federated performance review model — divisional CEOs and lab directors manage reviews locally. Clinical staff progress under HPSS Award increments; corporate staff have annual reviews.
Promotion Timeline & Hike
Performance Framework
Glassdoor Ratings
Medical-Led Culture
Sonic's federated model means career progression is often within a specific laboratory or division. Pathologists and scientists report high autonomy but limited cross-division mobility.
Key Nuances & Insights
Unlike centralized companies, Sonic's federated structure means compensation is set at the divisional/country level. A Lab Manager in Sydney may earn 30–50% more than one in Adelaide, and German pathologists are paid very differently from Australian ones. There is no single global pay grid.
Senior pathologists (A$500K–A$930K) earn 3–5x more than non-medical managers at the same organizational level. This dual-track system means the 'band' structure applies differently to clinical vs corporate staff. Nearly 400 pathologists in Australia alone drive significant salary mass.
The Health Professionals & Support Services Award 2020 guarantees minimum rates and annual increments for lab scientists, collectors, and technical staff in Australia. This means ~60% of Australian staff receive automatic pay progression regardless of company performance.
The combined A$14.3M in share sales by the outgoing CEO and long-serving CFO during FY2024 attracted investor scrutiny. While explained by the CEO's retirement context, the timing and scale were unusual for an ASX healthcare company. Goldschmidt retained A$14.7M in holdings.
FY2021 saw STI payouts at 150% of target — the maximum — driven by extraordinary COVID testing revenue. This was followed by a multi-year decline as COVID testing volumes normalized. The boom-and-bust cycle means historical STI data requires careful contextualization.
Sonic's commitment to 'medical leadership' means the CEO is always a qualified pathologist. This creates a distinct career trajectory where clinical excellence can lead to the top job — unlike most corporates where business/finance backgrounds dominate the C-suite.
The SPP (up to A$15,000 per eligible shareholder) allows rank-and-file staff to buy shares, often at a discount. Combined with the Employee Share Trust, this creates broader equity participation than the formal performance rights scheme which targets S5+ levels.
With operations in 8 countries across 5 currencies (AUD, USD, GBP, EUR, CHF), Sonic faces significant FX exposure in compensation. A$1 = ~US$0.62 means US pathologists earning US$350K are effectively earning A$565K — complicating global pay benchmarking.